PR93959

SALT LAKE CITY, Jan. 6, 2022 /PRNewswire=KYODO JBN/ --

DiscGenics (https://c212.net/c/link/?t=0&l=en&o=3404974-1&h=3114304150&u=https%3A%2F%2Fwww.discgenics.com%2F&a=DiscGenics), Inc.,

a privately held, clinical stage biopharmaceutical company focused on

developing regenerative cell-based therapies that alleviate pain and restore

function in patients with degenerative diseases of the spine, today announced

that Chief Executive Officer and Chairman Flagg Flanagan will present at the

40th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, 2022 at

9:00 a.m. EST.

Logo - https://mma.prnewswire.com/media/561675/DiscGenics_Logo.jpg

Invited attendees of the Conference can access the virtual session for both

live and on demand replay.

About DiscGenics

DiscGenics is a privately held, clinical stage biopharmaceutical company

focused on developing regenerative cell-based therapies that alleviate pain and

restore function in patients with degenerative diseases of the spine. As the

only company in the world to develop an allogeneic cell therapy derived from

intervertebral disc cells to treat diseases of the disc, DiscGenics believes it

has a unique opportunity to harness the restorative potential of the human body

to heal millions of patients suffering from the debilitating effects of back

pain. DiscGenics' first product candidate, IDCT, is a homologous, allogeneic,

injectable cell therapy that utilizes biomedically engineered progenitor cells

derived from intervertebral disc tissue, known as Discogenic Cells, to offer a

non-surgical, potentially regenerative solution for the treatment of patients

with mild to moderate degenerative disc disease. For more information, visit

www.discgenics.com.

SOURCE: DiscGenics, Inc.

CONTACT: Lindsey Saxon, lindsey@discgenics.com; Colin Novick (Japan),

colin.lee.novick@cj-partners.com